ANNUAL REPORT
2006/2007

THE HESS B. AND DIANE FINESTONE LABORATORY
IN MEMORY OF JACOB AND JENNY FINESTONE
http://www.mcgill.ca/finestone/

Submitted by: Dr. David S. Rosenblatt, Director
TABLE OF CONTENTS

MEMBERSHIP...........................................................................................................2
ANNUAL REPORT 2006/2007.....................................................................................4
MEETINGS AND PRESENTATIONS...........................................................................10
PUBLICATIONS.......................................................................................................17
RESEARCH OPERATING FUNDS..............................................................................24
FINANCIAL REPORT 2006/2007............................................................................26
MEMBERSHIP

PHYSICIANS AND SCIENTISTS

Ken Dewar          Kenneth Morgan
Eleanor Elstein    David S. Rosenblatt
William D. Foulkes Marc Tischkowitz
T. Mary Fujiwara   Patricia N. Tonin
Brian M. Gilfix    David Watkins

ADMINISTRATION

Maryse Bibeau       Yasmin Karim
Razia Chanda        Jenny Koulis
Maria Fiorito       Morgen Patterson
Vanessa Flannery    Danielle Veyre
Claire Goguen

CLINICAL SUPPORT STAFF

Suzanne Dufrasne    Maria Lalous (maternity leave Dec/06)
Maria Fiorito       Jocelyne Lavallée
Jennifer Fitzpatrick Laura Palma
Stephanie Fox       Laura Robb
Maria Galvez        Nora Wong
Angela Hosack       Sonya Zaor

RESEARCH SUPPORT STAFF

Suzanna Arcand      Kevin McKee
Joana Dias          Nicole Roslin
Nancy Hamel         Nelly Sabbagian
Kimberley Kotar     Zhen Shen
Mathieu Lemire      Jessica Wasserscheid
Lili Li             Daniel Yavin
I-Ching Lu

POST-DOCTORAL FELLOWS/CLINICAL FELLOWS

Yohan Bosse         Nicholas Dupre
Sarah Gail Buxbaum  Li Fan
Luca Cavallone      Claudia Gaspar
P. Campeau, MD      Karen Gambaro
Patrick Dion        Richard Le Blanc
Alexandre Montpetit
Laura Oksanen
Matthew Oughton
Tomi Pastinen

Michael Quinn
David Serre
André Toulous
Ahmet Yilmaz

GRADUATE STUDENTS

Faith Au-Yeung
Amanpreet Badhwar
Ashley Birch
Neal Cody
Patrick Cossette
Daniel Darmond
Adrian Diaz
Qingling Duan
Vincenzo Forgetta
Julie Gauthier
Abigail Gradinger
Heidi Howard
Margaret Illson
Tayma Khalil
Kathleen Klein
Peter Lee

Jordan Lerner-Ellis
Anastasia Levechenko
Amanda Loewy
Junhui Liu
Alexandre Marcil
Christianne Messaed
Emmanuel Mongin
Emily Moras
Emil Nashi
Nicole Palmour
Guillaume Pare
Isabelle Racine-Miousse
Saravanan Sundararajan
Paulina Wojnarowicz
Lama Yamani

SUMMER STUDENTS AND INDEPENDENT STUDIES STUDENTS

Emily Brown
Marie Caudrelier
Joanna Grater

Carter Li
David Novak
Rebecca Shapiro
ANNUAL REPORT 2006/2007

The Hess B. and Diane Finestone Laboratory in Memory of Jacob and Jenny Finestone exists in order to promote the field of medical genetics at McGill University. Dr. David S. Rosenblatt has been Director of the laboratory since its inception. The laboratory was established with the help of an endowment to McGill University and funding is used to advance the academic goals of the Division of Medical Genetics in the Department of Medicine of the McGill University Health Centre (MUHC). As such, this report also serves as the Annual Report of the Division of Medical Genetics of the Department of Medicine of the MUHC. It is available on the Internet (http://www.mcgill.ca/finestone). Since the University Division in Medicine also has included the Division at the Jewish General Hospital, this report also encompasses parts of that activity. Within the past few years, major advances have occurred with the creation of the Department of Medical Genetics at the Jewish General Hospital, and more recently, the Department of Medical Genetics at the MUHC.

Highlights: Research

**Dr. William Foulkes and Dr. Marc Tischkowitz** demonstrated the involvement of PALB2/FANCN in hereditary breast cancer families.

**Dr. David Rosenblatt** and his collaborators have shown that mutations in the MCEE gene can result in elevated methylmalonic acid excretion. With colleagues in the New York, he has described mutations in the PCFT gene in patients with Hereditary Folate Malabsorption, and with colleagues in Nebraska, he has shown that the polymorphic background of the MTRR gene affects the phenotype of a disease-causing mutation.

**Dr. Patricia Tonin** developed a derivative ovarian cancer cell line though the transfer of chromosome 3 fragments, using a novel modification of an established technique involving whole chromosome transfer. This cell line is now being used to identify the underlying chromosome 3p gene(s) involved in tumour suppression. A positive outcome has been the modulation of transcriptome networks, which will enable them to prioritize gene candidates for an independent project aimed at elucidating genes involved in ovarian tumourigenesis.

Highlights: Awards

**Dr. William Foulkes** was awarded a highly competitive Chercheur Nationaux Award from the FRSQ.

**Dr. Marc Tischkowitz** was awarded a Chercheur Clinicien Award from the FRSQ.
Highlights: Teaching

Dr. Nicholas AhMew completed the RV year of his training program and successfully passed the examinations of the Royal College in Medical Genetics. He plans to spend next year in China before continuing with fellowship training. Dr. Philippe Campeau completed his RIV year and served as Chief Resident. He is to be congratulated on an excellent job. Dr. Khalid Al-Tihihli, Dr. Maha Al-Awadi, and Dr. Mouna Ben Amor completed their RIII year and Dr. Daniela D’Agostino and Dr. Ahmad Alfares their RI year.

Highlights: Clinical

After more than five years, a Department of Medical Genetics was finally established at the MUHC. Dr. Teresa Costa has been appointed the first Chief of this hospital department. Dr. Costa has held positions in the past in Montreal, Halifax and Toronto.

In keeping with the new RUIS structure mandated by the Government of Quebec, a provincial committee and a local McGill committee have been established to examine how to best serve the interest of the Quebec population in the area of Medical Genetics.

Clinical Statistics:

Suzanne Dufrasne, M.Ps, Psychologist:

*Huntington Disease*

Number of new patients seen: 16  
Number of sessions in person: 28  
Number of counselling phone calls with patients (pre-session, follow-up): 48  
Number of counselling phone calls with health professionals: 20  
Total number of interventions with patients: 76

*Other Diseases (Creutzfeldt-Jakob, Familial adenomatous polyposis)*

Number of patients seen: 2

Stephanie Fox, MSc, MS, Genetic Counsellor:

*Montreal General Hospital Hereditary Cancer Clinic – April 1 to December 4, 2006:*

Number of new patients seen: 75  
Number of follow-up patients seen: 80  
Total cases seen: 155
Total Patients Seen at MUHC

2003-2004: 377
2004-2005: 376
2005-2006: 456
2006-2007: 451 (~20% increase since 2004-2005)

NOTES FOR LEGEND:
Fiscal periods are calculated from April 1st - March 31st.
- Totals for KASL (Lidia Kasprzak) take into account all patients seen by KASL and/or her replacements (SFOX [Stephanie Fox], MLAL [Maria Lalous], LROB [Laura Robb]) over each financial period.
- For 2005-2006 fiscal period, PALL (Laura Palma) totals are calculated from time of start date July 1, 2005 and therefore, do not include the statistics for April 1st - June 30th, 2005).
- Stats for RES include the total number of patients seen by either genetics residents and/or FITZJ (Jennifer Fitzpatrick)
Research Interests and Accomplishments of Individual Members:

**Dr. Eleanor Elstein** has an active clinic in the area of cardiovascular genetics, which evaluates inherited cardiac diseases as well as systemic genetic diseases that have cardiac manifestations.

**Dr. Ken Dewar** and his laboratory are using genomics and bioinformatics technologies to study genome structure and variation. One focus of the lab is to develop genetic mapping tools for investigating complex trait mapping in a nonhuman primate, the vervet monkey. Using comparative genomics approaches they have leveraged other genome projects (human, chimpanzee, rhesus monkey) to streamline the discovery of markers of genetic variation (SNPs). They have also embarked upon the generation of corresponding genome wide physical map, entailing the paired-end sequencing and genome alignments for >200,000 BAC clones. The vervet BAC map is being used to delineate chromosomal breakpoints and to identify vervet BAC clones associated with evolutionary recently derived centromeres and pericentromeric regions.

His group is also interested in understanding genome structure and virulence factors in the human bacterial pathogen *Clostridium difficile*. *C. difficile* remains a serious health risk in Quebec, North America, and Europe, in part due to an epidemic strain of increased virulence which has emerged in the last several years. The laboratory has performed the sequencing of the entire 4 Mb genome of a virulent strain from Montreal, and is now generating the genome sequences of other isolates with important clinical phenotypes. Cross-genome comparisons of gene content and organization will be used to identify additional candidate genes involved in pathogenicity.

**Dr. William Foulkes** and colleagues have been characterizing mutations in the new breast cancer gene PALB2. In addition, he has worked with BRCA1-mutated cell lines to try to develop novel treatments. With George Chong, he has described several novel mutations in genes associated with hereditary colorectal cancer. As mentioned above, in recognition of the excellence of his work, he has been awarded a Chercheur Nationaux award from the FRSQ.

**Mary Fujiwara** studies the distribution and maintenance of genetic variability, including deleterious alleles, in populations. During the current reporting period, she continued collaborations on the Hutterite population of North America, an inbred population isolate, to map and further delineate the clinical variability of a Joubert-related cerebello-oculo-renal syndrome. In addition, she participated in the mapping of two other rare Mendelian diseases, Sanfilippo C syndrome and methylmalonic aciduria and homocystinuria (cblC type), in patients and families collected from around the world. She also participated in collaborations on identifying underlying genetic susceptibility for complex diseases including kidney stone formation and early-onset coronary heart disease in the French-Canadian population.

She also collaborate with Daniel Bichet (Hôpital Sacré-Coeur de Montréal) on the genetics of nephrogenic and neurohypophyseal diabetes insipidus. The study of mutations in three different genes has shown that the mode of inheritance can differ based on the particular mutation. They maintain locus specific mutation databases for these genes which encode the hormone arginine vasopressin, its receptor, and a water channel (*AVP*, *AVPR2*, and *AQP2*, respectively).
**Dr. Brian Gilfix** focuses on two main areas of research: 1) Homocysteine and its Metabolism/Inborn Errors of Metabolism (Homocystinuria)-they have a large cohort of patients in the Adult Genetics Clinic with homocystinuria. He is using this opportunity to explore new treatments of homocystinuria and investigate the effect of elevated homocysteine on other risk factors for cardiovascular disease; 2) Development of Laboratory Methods in Molecular Diagnostics and HPLC-he is developing and implementing assays based on hybridization probes to replace standard assays based on restriction fragment length polymorphism used to genotype single nucleotide polymorphisms in the clinical laboratory. The benefit of this is decreased net cost and faster turnaround time.

**Dr. Ken Morgan** has a major interest in human population genetics and genetic epidemiology. He is involved in the genetic analysis of Mendelian and complex traits in humans and mice. Accomplishments related to human genetics include mapping rare Mendelian diseases. Ongoing collaborations include segregation and linkage analysis of intermediate phenotypes contributing to calcium kidney stone formation; genetic susceptibility to inflammatory bowel disease in children; and reducing the complexity of pedigrees in founder populations such that statistical analysis is computationally feasible.

He is a member of the CIHR Institute of Genetics Priorities and Planning committee for genetic epidemiology and statistical genetics and was on the organizing committee of the “Second Annual Canadian Genetic Epidemiology and Statistical Genetics Meeting”, held in Toronto, 15-17 April 2007.

**Dr. David Rosenblatt** and his laboratory continue to be the major international referral source for the diagnosis of patients with inherited disorders of folate and vitamin B12. They are involved in studying the biochemical and molecular bases of these diseases. This year they have expanded mutation analysis among patients with combined homocystinuria and methylmalonic aciduria due to mutations in MMACHC. They have also shown that mutations in the MCEE gene can result in elevated methylmalonic acid excretion. With colleagues in the New York, they have described mutations in the *PCFT* gene in patients with Hereditary Folate Malabsorption, and with colleagues in Nebraska, they have shown that the polymorphic background of the MTRR gene affects the phenotype of a disease-causing mutation. Dr. Rosenblatt continues to serve as Chairman of the Department of Human Genetics. In August 2006, he served as the Chairman of the FASEB Summer Research Conference on One-Carbon Metabolism in Indian Wells, California.

**Dr Marc Tischkowitz** has been establishing a research program at the Segal Centre, Jewish General Hospital to undertake innovative and effective research in the field of hereditary predisposition to cancer, with a focus on the genetic links between breast cancer and Fanconi Anemia. He was part of an international collaboration that identified PALB2/FANCN as a new Fanconi Anemia gene and together with Dr Foulkes he helped to establish that PALB2 is a breast cancer predisposition gene.
**Patricia Tonin** works in two principal areas of research; these are described on the web site: [www.toninlab.mcgill.ca](http://www.toninlab.mcgill.ca).

**A. The Molecular study of Human Epithelial Ovarian Cancer**

More than 70% of women diagnosed with ovarian cancer die of the disease. Our knowledge of the molecular events associated with the development and progression of epithelial ovarian cancer has been limited by the lack of a suitable model system. Also, since the disease is often diagnosed at a late stage when numerous complex chromosomal changes have already taken place, the early molecular events remain largely unknown. Research in the lab is focused on the identification of tumour suppressor genes, particularly those physically associated with chromosomes 3p and 17q. Various molecular genetic techniques are used to identify them, which include, allelic content analysis such loss of heterozygosity studies and single nucleotide (SNP) polymorphism analyses, large-scale gene expression assays (Affymetrix platform), and more recently functional approaches based on chromosome transfer fragment and gene complementation. A major accomplishment of the last year was development of a derivative ovarian cancer cell line though the transfer of chromosome 3 fragments. This cell line was developed using a novel modification of an established technique involving whole chromosome transfer. This cell line is now being used to identify the underlying chromosome 3p gene(s) involved in tumour suppression. A positive outcome has been the modulation of transcriptome networks, which will enable them to prioritize gene candidates for an independent project aimed at elucidating genes involved in ovarian tumourigenesis. [See News item at [www.toninlab.mcgill.ca](http://www.toninlab.mcgill.ca) for Press Release.]

In collaboration with colleagues at the CHUM-Notre Dame, they investigate gene expression profiles of ovarian cancer samples with the aim of identifying signature patterns of gene expression in order to elucidate molecular pathways important in ovarian tumourigenesis.

**B. Breast and Ovarian Cancer Susceptibility Genes**

Hereditary breast and ovarian cancer accounts for approximately 5-10% of all breast and ovarian cancers. A large majority of cancer families are attributed to germline mutations in BRCA1 and BRCA2. However, about 40% of cancer families are negative for mutations in these known genes. Dr. Tonin’s group is also focused on determining the contribution of known and unknown cancer susceptibility genes to inherited predisposition to breast and ovarian cancer. They focus on the founder French Canadian population of Quebec as reviewed in a special issue of the *Bulletin du Cancer*, which commemorated the 100th anniversary of *Société Française du Cancer* in France. In 2006 they described a new founder BRCA2 mutation found to recur in the French Canadian population. Moreover, they have extended their analysis to further refine those cancer families most likely to harbour BRCA1 or BRCA2 mutations.
MEETINGS AND PRESENTATIONS

KEN DEWAR

February 23, 2006 Department of Physiology Seminar Series, McGill University, Montreal, QC
**Title:** Comparative Genomics: Comparing and contrasting aspects of genome evolution

November 26, 2006 Academic Tribute and Colloquium in Honor of Dr. Abraham Fuks
McGill University, Montreal QC
**Title:** I have 50% of my mother’s genes, yet am 99% identical to a chimpanzee

SUZANNE DUFRASNE

November 21, 2006 Seminar for Genetic Counselling students, with Dr. Sylvain Chouinard.
Ste-Justine Hospital, Montreal, QC
**Title:** Predictive testing for Huntington Disease

WILLIAM FOULKES

February 2, 2006 5th International “From Gene to Cure” Congress
Vrije Universiteit Amsterdam
Amsterdam, Netherlands
**Title:** Genetic Risk Assessment

February 2, 2006 5th International “From Gene to Cure” Congress
Vrije Universiteit Amsterdam
Amsterdam, Netherlands
**Title:** Prevention of hereditary breast cancer

June 15, 2006 Toronto Breast Cancer Symposium 2006
Metro Toronto Convention Center
Toronto, Ontario
**Title:** Genetics and Breast Cancer: An Update

April 20, 2006 “Basal-like and BRCA1-associated Breast Cancer” meeting
Harvard Club
Boston, MA, USA
**Title:** Clinico-pathological features of basal-like/BRCA1 tumors

August 16, 2006 Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia
Couran Cove Island Resort
Stradbroke Island, Australia
**Title:** Recent advances in understanding of the inherited susceptibility to cancers of the prostate, pancreas, stomach and colorectum

August 18, 2006  
Australian Ovarian Cancer Study and the Family Cancer Clinics of Australia  
Couran Cove Island Resort  
Stradbrooke Island, Australia  
**Title:** Hereditary breast cancer: from pathology to treatment and beyond

October 28, 2006  
10th Annual Cincinnati Comprehensive Breast Cancer Conference  
Cutting Edge Strategies in Breast Cancer: The next decade  
Cincinnati, OH, USA  
**Title:** Breakthrough treatments for BRCA1 and BRCA2 mutation carriers

November 9, 2006  
Cancer Colloquia IV: Cell and Molecular Biology of Breast Cancer  
University of St-Andrews  
St-Andrews, Scotland  
**Title:** Hereditary breast cancer: from pathology to treatment and beyond

**BRIAN GILFIX**

October 6, 2006  
McGill Neurology Conference  
Montreal General Hospital  
Montréal, QC  
**Title:** Myelopathy due to vitamin B12 deficiency

November 14, 2006  
Speaker, Life as a Physician Seminar Series  
McGill Faculty of Medicine  
Montréal, QC

**KENNETH MORGAN**

August 3-5, 2006  
Origins Institute, McMaster University  
Hamilton, Ontario  
**Title:** Challenges and approaches to understanding complex diseases.

October 19, 2006  
Invited speaker at conference: Innovations in Genomics Research: Implications for Health Services and Policy  
Newfoundland and Labrador Centre for Health Services and Policy  
St. John’s, Newfoundland  
**Title:** Population history, structure and genetics of the Hutterites in North America.
LAURA PALMA

October 9-13, 2006  The American Society of Human Genetics, 56th Annual Meeting
Ernest N. Morial Convention Center, New Orleans, LA
Attendee

January 12, 2007  Multidisciplinary Urology/Genetics Rounds
Montréal, QC
Title: Genetics of Pheochromocytoma and other Paragangliomas

May 4, 2007  Medical Genetics Journal Club
Montréal, QC
Title: Assisted reproduction for inherited predisposition to cancer:
Challenging the barriers of preventive medicine?

DAVID ROSENBLATT

August 5-10, 2006  FASEB Summer Research Conference
One Carbon Metabolism
Indian Wells, California.
Chairman

September 11, 2006  National Council of Jewish Women of Canada
Gelber Conference Centre, Montreal, QC
Moderator: Women and Health: Unravelling the Mysteries of Hormones

Sept 26-29, 2006  Canadian Academy of Health Sciences
2nd Annual Meeting
Ottawa, ON

October 6-7, 2006  Genetic Testing
Center for Disease Control (CDC)
Atlanta, GA

April 19-22, 2007  Canadian Genetic Diseases Network
16th Annual Meeting
Saint-Sauveur, Quebec
Title: Inborn errors of vitamin B12: From clinical phenotypic variability
to novel metabolic steps.
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Location</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2006</td>
<td>CBCRA Reasons for Hope Conference, Presentation with Jean-Sébastien Brunet, Louis R Bégin, David Huntsman, Maggie CU Cheang, Torsten Nielsen, Lars Akslen and William D Foulkes</td>
<td>Montréal, QC</td>
<td>The <em>BRCA1</em>-associated “core basal phenotype” (ER-, HER2-, CK5/6+) of breast cancer is associated with a poor prognosis.</td>
</tr>
<tr>
<td>May 2, 2006</td>
<td>Réseau de Médicine Génétique Appliquées du FRSQ Journées Génétiques Meeting</td>
<td>Montréal, QC</td>
<td>BRCA1-associated “core basal phenotype” (ER-, HER2-, CK5/6+) of breast cancer is associated with a poor prognosis</td>
</tr>
<tr>
<td>May 6, 2006</td>
<td>Montreal Children’s Hospital Friday Lecture and Seminar Series</td>
<td>Montréal, QC</td>
<td>Chromosome Breakage Syndromes and DNA repair</td>
</tr>
<tr>
<td>May 8, 2006</td>
<td>Polymnia Galiatsatos, Adrian Gologan, Marc Tischkowitz</td>
<td>Jewish General Hospital Medical Rounds</td>
<td>HNPCC: Diagnostic criteria and more…</td>
</tr>
<tr>
<td>September 22</td>
<td>Hôpital Charles LeMoyne Oncology Rounds</td>
<td>Montréal, QC</td>
<td>An update on Hereditary Breast Cancer</td>
</tr>
<tr>
<td>October 26, 2006</td>
<td>Montreal Centre for Experimental Therapeutics in Cancer, 4th Annual Meeting</td>
<td>Montréal, QC</td>
<td>What’s new in DNA Repair?</td>
</tr>
<tr>
<td>October 19-22, 2006</td>
<td>Speaker, 18th Annual Fanconi Anemia Scientific Symposium</td>
<td>North Bethesda, Maryland, USA</td>
<td></td>
</tr>
<tr>
<td>November 10, 2006</td>
<td>Jewish General Hospital Obstetrics and Gynecology Rounds</td>
<td>Montréal, QC</td>
<td>Screening for genetic diseases in the Ashkenazi Jewish population</td>
</tr>
<tr>
<td>December 14, 2006</td>
<td>McGill Thursday Evening Lecture Series</td>
<td>Montréal, QC</td>
<td>Genetic factors in breast and ovarian cancer: a primer for family doctors</td>
</tr>
</tbody>
</table>
February 15, 2007  Genetic Counselling Students Seminar  
McGill University  
Montreal, QC  
**Title:** Pathology in Cancer Genetics

February 16, 2007  Montreal Children’s Hospital Friday Lecture and Seminar Series  
Montreal, QC  
**Title:** Screening for genetic diseases in the Ashkenazi Jewish population

February 26, 2007  Jewish General Hospital Medical Rounds (also presented at Montreal General Hospital and Royal Victoria Hospital)  
Montréal, QC  
**Title:** A stitch in time? Management issues in hereditary gastric cancer

March 6, 2007  Environmental Carcinogenesis, MSc Course EXMD 614  
McGill University  
Montreal, QC  
**Title:** It's a dangerous world out there: DNA repair and environmental toxins

March 23, 2007  Montreal Children’s Hospital Genetics Rounds, with Sonya Zaor  
Montreal, QC  
**Title:** Dilemmas in Hereditary Gastric Cancer - a new case and an old case revisited

April 13, 2007  McGill University Hospitals Research Institute Genetics Axis  
McGill Department of Human Genetics Seminar Series  
Montreal, QC  
**Title:** PALB2/FANCN – another link between Fanconi Anemia and breast cancer

April 13, 2007  Montreal Children’s Hospital Neonatal Rounds  
Montreal, QC  
**Title:** Fanconi anemia - an important cause of congenital malformations

May 16, 2007  “Lets Talk about Colorectal Cancer” - Free Public Forum: Chevra Kadisha B’nai Jacob - Beit Hazikaron and Colorectal Association of Canada  
**Title:** Genetics of Colorectal Cancer

May 27, 2007  30-minute interview, Radio 940  
Montreal, QC  
**Title:** Hereditary predisposition to breast cancer
May 27, 2007  
Public Seminar, Salon des Baby Boomers Plus, Palais des congrès  
Montréal, QC  
**Title:** Cancer- Are you at risk? Can you prevent it?

---

**PATRICIA N. TONIN**

May 18, 2006  
CHUM-Hopital Hotel Dieu - Service de Médecine Génique  
Montreal, Quebec  
**Title:** The importance of chromosome 3 genes in ovarian cancer revealed by integrating genomic and functional strategies

May 1-2, 2006  
Réseau de médecine génétique appliquée (RGMA) du FRSQ  
6èmes Journée Génétiques  
**Title:** The influence of the BRCA2 ovarian cancer cluster region (OCCR) in French Canadian breast and/ovarian cancer families of Quebec

May 13-16, 2006  
Canadian Conference on Ovarian Cancer Research  
Third National Conference On Ovarian Cancer Research,  
Vancouver, British Columbia  
**Title:** Histopathological subtypes of ovarian cancers in familial breast-ovarian cancer families: Are there novel breast-ovarian cancer susceptibility genes?

March 20, 2007  
Cancer Research Laboratory Program, London Regional Cancer Program  
London Health Sciences Centre  
London, Ontario  
**Title:** Integrating genomic, gene expression and functional complementation strategies to identify genes implicated in ovarian cancer

---

**NORA WONG**

April 18, 2007  
Public Service Announcement  
Minimed-SMBD-Jewish General Hospital  
April 11, 18, 25 & May 2, 9, 16  
Montréal, QC  
**Title:** Medical Genetics-Genetic risk and cancer

---

May 31, 2007  
Session A: Research in cancer patient education
Marriott Château Champlain
Montreal, QC
Title: Cancer prevention Education: Insights from genetics and lifestyle changes

SONYA ZAOR

March 23, 2007 McGill Medical Genetic Grand Rounds with Marc Tischkowitz
Montréal, QC
Title: Dilemmas in Hereditary Gastric Cancer - a new case and an old case revisited.
ORIGINAL PUBLICATIONS


Tonin PN. Le spectre limité des mutations pathogéniques BRCA1 et BRCA2 dans le cancer du sein et le cancer du sein-ovaire dans les familles canadiennes-françaises, une population fondatrice du Québec, Canada [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada]. Bulletin du Cancer 93:841-6, 2006 [Invited review, for special issue to commemorate 100th anniversary of Société Française du Cancer en 2006]


### RESEARCH OPERATING FUNDS – 2006-2007

**AGENCY**

<table>
<thead>
<tr>
<th>Name</th>
<th>Agency/Grant Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dewar, Ken</td>
<td>Genome Canada, Group Grant – 2006-2009</td>
</tr>
<tr>
<td></td>
<td>Genome Canada, PI – 2005-2009</td>
</tr>
<tr>
<td></td>
<td>CIHR, Group Grant – 2005-2008</td>
</tr>
<tr>
<td></td>
<td>National Institutes of Health, PI, Group Grant – 2004-2008</td>
</tr>
<tr>
<td></td>
<td>Genome Canada (Emerging Issues), PI – 2006-2007</td>
</tr>
<tr>
<td></td>
<td>Canada Foundation for Innovation, PI, Group Grant – 2006-2007</td>
</tr>
<tr>
<td>Brian Gilfix</td>
<td>Gustuv Levinschi Foundation Award, PI – 2007</td>
</tr>
<tr>
<td></td>
<td>March of Dimes Birth Defects Foundation, PI – 2006-2008</td>
</tr>
<tr>
<td></td>
<td>CBCRA, Operating Grant, PI – 2006-2009</td>
</tr>
<tr>
<td></td>
<td>CBCRA, Operating Grant, PI – 2005-2008</td>
</tr>
<tr>
<td></td>
<td>CIHR, Operating Grant, (PI as of 12/18/06) – 2003-2006, extended 2007</td>
</tr>
<tr>
<td></td>
<td>NIH, Group Grant, Co-Investigator – 2002-2006, extended 2007</td>
</tr>
<tr>
<td></td>
<td>CIHR, Group Grant, Co-Investigator – 2003-2007</td>
</tr>
<tr>
<td></td>
<td>PCRFC, Operating Grant, Co-Investigator – 2005-2007</td>
</tr>
<tr>
<td></td>
<td>CBCRI, Operating Grant, Co-Investigator – 2004-2009</td>
</tr>
<tr>
<td>Morgan, Kenneth</td>
<td>Networks of Centres of Excellence, Operating, Investigator – 1999-2009</td>
</tr>
<tr>
<td></td>
<td>CIHR, Group Grant, Investigator – 2003-2008</td>
</tr>
<tr>
<td></td>
<td>CIHR, Operating Grant, Co-PI – 2006-2009</td>
</tr>
<tr>
<td></td>
<td>CIHR, Operating Grant, Co-application – 2007-2009</td>
</tr>
<tr>
<td>Rosenblatt, David S.</td>
<td>CIHR, Operating Grant, PI – 2006-2009</td>
</tr>
<tr>
<td></td>
<td>CIHR, Group Grant, Co-Investigator – 2007-2012</td>
</tr>
</tbody>
</table>
Tischkowitz, Mark
Rethink Breast Cancer, Operating Grant, PI – 2006-2008

Tonin, Patricia N.
CIHR, Operating Grant, Investigator – 2005-2008
Quebec Breast Cancer Foundation, Group Operating Grant – 2004-2007
CIHR, Operating Grant, Investigator – 2004-2006
Fonds de la Recherche en Santé du Québec: Reseau cancerologie, Group Operating Grant – 2000-2007
VRQ, Group Operating Grant – 2002-2006
Canadian Foundation for Innovation, Innovation Fund – 2002-2006
Montreal Breast Cancer Foundation, Group Operating Grant – 2003-2006
FINANCIAL REPORT – 2006/2007

Starting Balance $ 87,772
Deficit from 2005-2006 ($18,637)

$ 69,135

Salary Support and Benefits
(Dufrasne, Flannery, Rosenblatt, Valancy, Veyre) $ 48,909

Conferences, Seminars, Travel $ 18,195

Catering and Events $ 2,699

Library and Membership $ 6,320

Board Accreditation
(Fox, Palma, Secord) $ 6,955

Materials and Supplies $ 1,321

Miscellaneous $ 1,941

Total Expenses: $ 86,340

Balance: ($17,205)